The Psychiatric Care Gap in Perinatal Mental Health

Approximately half of perinatal patients with a PMAD that warrants medication treatment do not receive it. This is not primarily a screening problem. Practices that screen adequately for PMAD still refer patients to a prescribing pipeline that has months-long wait times, inadequate insurance coverage, or no perinatal-trained prescribers accessible at all. The gap is at the treatment access level, and it is structural.

Providers who can name the gap and understand its components are in a better position to close it for their patients.

---

The Scope of the Problem

Perinatal mood and anxiety disorders affect an estimated 600,000 to 900,000 patients annually in the United States, based on prevalence estimates of 15 to 20% of postpartum patients. Moderate-to-severe presentations, which are most likely to benefit from pharmacological treatment, represent a substantial subset of these cases.

Population studies on treatment rates consistently show that fewer than half of patients with PMAD that meets criteria for medication receive antidepressant therapy. Treatment rates are lower in BIPOC and low-income populations, where PMAD prevalence is simultaneously higher. The combination of higher disease burden and lower treatment access is not coincidental; it reflects differential access to both prescribers and insurance coverage in communities that face the greatest structural barriers.

The gap exists even in practices that screen well. An OB practice that administers the EPDS at every postpartum visit and identifies every score-positive patient has not solved the treatment problem if the referral pathway those patients are sent into has an 8-week wait time. Identification is necessary but not sufficient.

---

What Creates the Gap

The prescribing gap has multiple contributing causes that interact and compound each other.

Perinatal psychiatry workforce shortage. There are an estimated 3,000 to 4,000 practicing perinatal psychiatrists in the United States. With 3 to 4 million deliveries annually, the patient-to-specialist ratio makes universal psychiatric management of PMAD mathematically impossible. Most general psychiatrists have limited familiarity with postpartum pharmacology, breastfeeding drug safety, and the specific clinical presentations that characterize PMADs. This creates a functional shortage that is larger than the raw headcount implies. In many markets, perinatal psychiatry wait times are 8 to 16 weeks or longer.

OB hesitancy to prescribe. ACOG explicitly supports OB initiation of SSRIs for uncomplicated moderate PPD as a response to the psychiatric workforce shortage. Despite this, many OBs defer to psychiatry without a realistic assessment of how long that access will take. The deferred responsibility produces a gap: the patient is told to see a psychiatrist, the wait is months, and she remains in an acute untreated episode while the appointment is pending. The OB who could have initiated sertraline at the six-week visit did not, not because it was outside scope, but because it was outside habit.

Patient ambivalence about medication. Particularly for breastfeeding patients or patients with a prior negative medication experience, ambivalence about antidepressants is common. This ambivalence is addressable with clinical counseling, but it rarely receives direct, specific engagement. A provider who says "there are some options we can discuss" and then refers out has not engaged the ambivalence. A provider who provides specific relative infant dose data and a direct framing of the risk-benefit comparison is more likely to reach a patient who would benefit from treatment.

Insurance and access barriers. Perinatal psychiatrists are disproportionately concentrated in urban markets and are disproportionately out-of-network. Even patients who can find a perinatal prescriber may face cost barriers that make the appointment unreachable. Telehealth has expanded geographic access without resolving the coverage and cost issues.

---

What the Research Shows About OB Prescribing

OBs who are trained to initiate first-line SSRIs for PPD achieve comparable outcomes to psychiatrist-initiated treatment for uncomplicated moderate PPD. This is not a controversial finding in the perinatal mental health literature; it reflects the clinical reality that uncomplicated moderate PPD responds predictably to first-line SSRIs, and the prescribing decision in these cases does not require specialist-level expertise.

ACOG Practice Bulletin 92 and subsequent guidance explicitly address OB prescribing for PPD as appropriate care when psychiatric referral is unavailable or substantially delayed. The boundary for OB prescribing is clear: uncomplicated moderate PPD (EPDS approximately 13-18), no prior treatment failure, no significant psychiatric comorbidity, no history suggesting bipolar disorder, no active suicidal ideation with plan. These criteria are achievable for most patients who screen positive through OB practice.

For presentations that fall outside this boundary: prior treatment failures, comorbid bipolar or psychosis, complex medication histories, or breastfeeding safety questions the OB is not confident managing , psychiatry referral is appropriate. The distinction is between deferring all medication decisions to psychiatry as a default, and deferring only the cases that genuinely require specialist expertise.

---

What Social Workers Can Do

Hospital social workers embedded in or affiliated with OB practices are positioned to advocate for medication conversations when OBs have not raised them. This is within scope for a social worker who is conducting a psychosocial assessment of a score-positive patient and observes that the OB encounter did not include a medication discussion.

A social worker who says to a patient "Your score today was in the range where medication is sometimes helpful , has your doctor talked to you about that?" is not prescribing. She is facilitating a conversation that should have happened and did not. For patients who express that they were not offered medication, or who ask about it, the social worker can prompt the OB to have that conversation at the same visit.

Social workers who identify that patients are waiting months for a psychiatry appointment for a presentation an OB could manage are also positioned to advocate for the OB to initiate treatment while the psychiatry appointment is pending. Bridging treatment during an access gap is both clinically appropriate and patient-protective.

---

A Practical Framework for Closing the Gap in Your Practice

For OBs: Identify which presentations you are currently deferring to psychiatry that fall within the uncomplicated moderate PPD range. For each of those cases, the relevant question is whether the patient will actually reach a prescriber within the treatment window if referred. If the answer is often no, OB-initiated treatment is the clinically appropriate response.

For social workers: Build awareness of what the OB prescribing criteria are so you can advocate accurately. A social worker who knows that uncomplicated moderate PPD with EPDS 13-18 is within OB scope is more effective at advocacy than one who treats all medication questions as outside her lane.

For both: Identify the bottleneck in your referral pathway. Is it prescriber access? Insurance? Patient ambivalence? Each bottleneck has a different response, and naming it is the precondition for addressing it.

For practices looking to connect patients with perinatal mental health support alongside any prescribing that is already in place, Phoenix Health provides therapy and coordinates with prescribers. Visit our referral and partnerships page to explore a referral relationship.

For prescribing guidance on OB-initiated SSRIs for postpartum depression, see when OBs should initiate SSRIs for postpartum depression.

---